CircRNA Synthesis Market Size, Trends, Share and Forecast 2032

CircRNA Synthesis Market Overview:

The global CircRNA Synthesis Market size was estimated at USD 189.75 million in 2025 and is expected to reach USD 527 million by 2032, growing at a CAGR of 15.7% from 2025 to 2032, following the required structure in your prompt file. The strongest growth driver is the accelerating adoption of circular RNA constructs in advanced therapeutics programs, where improved RNA stability and sustained expression profiles increase demand for reliable synthesis workflows across discovery and development. CircRNA Synthesis Market expansion is also supported by broader RNA platform investments across established biopharma and emerging biotech ecosystems.

Key Market Trends & Insights

• CircRNA Synthesis Market is projected to expand from USD 189.75 million in 2025 to USD 527 million by 2032, reflecting a 15.7% CAGR over 2025–2032.
• North America accounted for the largest regional share of 42.8% in 2025, reflecting concentration of RNA-therapy R&D and commercial procurement in the region.
• Reagents & Kits accounted for the largest share of 44.6% in 2025, supported by recurring consumable demand across circularization, purification, and QC workflows.
• Therapeutics Development held the largest application share of 61.2% in 2025, driven by expanding use of circRNA constructs for vaccine, oncology, and rare-disease research pipelines.
• Pharmaceutical and Biotechnology Companies represented the largest end-use share of 56.8% in 2025, reflecting higher spend intensity and outsourcing requirements for complex synthesis.

Segment Analysis

CircRNA Synthesis Market demand is shaped by two procurement patterns: high-frequency purchases of workflow-critical consumables and an increasing preference for outsourcing specialized steps. Reagents and kits remain central because circRNA synthesis requires multiple steps such as template preparation, circularization, purification, and verification, and each step drives repeat consumption. Instruments contribute through analytical validation and process standardization, especially where buyers aim to improve reproducibility and documentation.

Application demand is anchored in therapeutics development, where circRNA stability and potential for longer-lived expression support use in next-generation RNA modalities. Drug discovery demand is supported by broader exploratory use of synthetic circRNAs for target validation and screening models, especially when programs require rapid design iterations. Other applications include method development, academic hypothesis testing, and platform benchmarking.

End-use trends indicate biopharma buyers increasingly pursue integrated offerings that combine design support, synthesis execution, purification, and quality checks. Academic and research institutes expand adoption as tools become more accessible and as collaborations with biotech translate basic research into preclinical programs. Other end users participate through translational research, platform services, and early-stage proof-of-concept projects.

By Product & Service Insights

Reagents & Kits accounted for the largest share of 44.6% in 2025. Reagents & Kits lead because circRNA synthesis workflows require consistent enzymes, buffers, circularization reagents, and purification inputs across repeated experimental cycles. Reagents & Kits also benefit from standardized protocols that improve reproducibility across labs and reduce batch-to-batch variability concerns. Service providers frequently bundle proprietary consumables into service delivery, which further sustains reagent demand alongside outsourcing growth.

By Application Insights

Therapeutics Development accounted for the largest share of 61.2% in 2025. Therapeutics Development leads because circRNA constructs are evaluated for improved stability and sustained protein expression, which aligns with therapeutic modality needs across multiple disease areas. Therapeutics Development programs also demand higher-quality synthesis and tighter quality controls, which increases spend per project relative to exploratory work. Therapeutics Development activity is reinforced by platform-level investments where circRNA is assessed alongside other RNA formats for performance and manufacturability.

By End Use Insights

Pharmaceutical and Biotechnology Companies accounted for the largest share of 56.8% in 2025. Pharmaceutical and Biotechnology Companies lead because pipeline programs require scalable synthesis, consistent characterization, and rapid iteration across multiple constructs and indications. Pharmaceutical and Biotechnology Companies also adopt outsourcing models to access specialized expertise for circularization, purification, and quality verification steps. Pharmaceutical and Biotechnology Companies typically maintain higher procurement budgets and prioritize standardized documentation, which increases demand for validated workflows and supplier reliability.

CircRNA Synthesis Market Drivers

Expansion of RNA therapeutics pipelines and platform diversification

CircRNA Synthesis Market growth is supported by expanding RNA-based therapeutic pipelines that include exploration of circular RNA for stability and sustained expression advantages. CircRNA Synthesis Market adoption rises when therapeutic programs require multiple construct iterations, rapid turnaround, and reproducible synthesis outcomes. CircRNA Synthesis Market demand also benefits from platform diversification trends in which developers evaluate multiple RNA formats to optimize performance for different indications. CircRNA Synthesis Market purchasing increases as programs move from feasibility studies into preclinical development with higher quality expectations.

• For instance, Orna Therapeutics screened thousands of IRES elements across multiple primary human cell types using its FoRCE platform, ultimately enabling its lead oRNA program ORN-101 to achieve tumor eradication in mouse models at 10–20-fold lower doses than earlier construct versions demonstrating how iterative construct diversification across multiple RNA formats directly drives demand for high-throughput, reproducible synthesis capacity.

Increasing outsourcing of complex synthesis and characterization steps

CircRNA Synthesis Market demand strengthens as buyers outsource specialized workflow steps such as circularization optimization, purification strategy selection, and verification testing. CircRNA Synthesis Market service uptake is reinforced by the need to shorten timelines and reduce internal method-development burden. CircRNA Synthesis Market suppliers that provide integrated design-to-QC offerings reduce operational friction for customers managing multiple candidates. CircRNA Synthesis Market growth is further supported when outsourcing converts fixed costs into variable costs aligned to pipeline milestones.

Rising need for standardized, reproducible workflows across research settings

CircRNA Synthesis Market expansion is driven by the need for standardized and reproducible workflows across labs, particularly where programs require cross-site comparability. CircRNA Synthesis Market buyers prioritize kits and validated processes that reduce variability across runs and improve experimental confidence. CircRNA Synthesis Market instrument utilization supports documentation and validation of synthesis outcomes through analytical confirmation steps. CircRNA Synthesis Market procurement strengthens as organizations formalize quality procedures and strengthen traceability requirements.

Greater accessibility of synthesis toolkits and vendor ecosystems

CircRNA Synthesis Market growth is enabled by broader availability of commercial toolkits, catalog reagents, and customizable service menus that simplify adoption. CircRNA Synthesis Market demand increases when suppliers lower technical barriers through protocols, troubleshooting support, and modular workflow options. CircRNA Synthesis Market expansion is supported by vendor ecosystems that combine materials, instruments, and services for end-to-end execution. CircRNA Synthesis Market adoption accelerates as more buyers gain confidence that circRNA synthesis can be implemented without extensive in-house specialization.

• For instance, GenScript structured its circRNA synthesis offering as a modular service menu with off-the-shelf construct options for fast delivery, insert sequence lengths from 100 bp to 4 kb, and batch scales from 200 µg to 10 mg with entry-level pricing starting at $800 per 25 µg allowing academic labs and early-stage biotechs to access functional circRNA without developing internal IVT or HPLC purification capability.

CircRNA Synthesis Market Challenges

CircRNA Synthesis Market faces technical challenges related to achieving consistent circularization efficiency, minimizing impurities, and validating product integrity across different sequence designs. CircRNA Synthesis Market buyers often encounter variability risks when scaling from exploratory synthesis to more controlled workflows, which can increase repeat work and costs. CircRNA Synthesis Market complexity also increases when workflows must be adapted for different constructs, as optimization requirements can be sequence-specific. CircRNA Synthesis Market growth can be constrained when teams lack experienced staff to design robust protocols and interpret characterization results.

• For instance, TRIC-V2 circularization experiments showed that extending stem length from 5 bp (V1.0) to 25 bp raised circularization efficiency to 97.8% at 8 minutes with a yield of 74.8%, yet further extending the external guide sequence beyond 40 nucleotides produced no measurable gain demonstrating that each nucleotide-level design decision can have non-linear effects on outcome, requiring re-optimization per construct.

CircRNA Synthesis Market also experiences operational and procurement constraints tied to quality expectations and supply continuity for specialized reagents. CircRNA Synthesis Market projects can face delays when lead times for critical enzymes, purification materials, or verification tools increase. CircRNA Synthesis Market adoption in smaller labs can be limited by budget constraints, particularly when workflows require both consumables and instruments. CircRNA Synthesis Market suppliers must balance customization needs with standardized delivery models, which can pressure margins and delivery timelines.

CircRNA Synthesis Market Trends and Opportunities

CircRNA Synthesis Market trends indicate rising demand for integrated offerings that combine construct design guidance, synthesis execution, purification, and verification within a single vendor workflow. CircRNA Synthesis Market customers increasingly prefer partners that can support iterative design cycles and provide consistent documentation for internal reviews. CircRNA Synthesis Market opportunity expands as service models mature and as buyers seek predictable turnaround times across multiple projects. CircRNA Synthesis Market suppliers can differentiate through standardized QC packages and scalable production options aligned to development stages.

• For instance, GenScript offers custom circRNA synthesis for insert sequences from 100 bp to 4 kb with delivery in 3 weeks, and the company reports typical circularization efficiency of 60% to 90% along with HPLC purification yields of around 20% to 40%.

CircRNA Synthesis Market opportunity is also supported by expanding adoption beyond early research into more structured preclinical workflows where repeatability and traceability become central. CircRNA Synthesis Market vendors can expand by offering modular product bundles that match buyer maturity, from entry-level kits to advanced purification and analytics support. CircRNA Synthesis Market growth can benefit from education-led commercialization such as protocols, training, and application notes that reduce adoption friction. CircRNA Synthesis Market regional opportunity strengthens as Asia Pacific ecosystems expand and as collaboration networks increase cross-border demand.

Regional Insights

North America

North America held a 42.8% share of CircRNA Synthesis Market revenue in 2025. North America demand is supported by higher concentration of RNA-therapeutics programs, established procurement budgets, and strong adoption of outsourcing for specialized synthesis steps. North America also benefits from dense supplier ecosystems that support faster iteration cycles and service availability.

Europe

Europe accounted for 31.9% of CircRNA Synthesis Market revenue in 2025. Europe demand is supported by strong academic research bases and established biopharma clusters that sustain both consumable purchases and service utilization. Europe also shows structured adoption through collaborations that translate early research into applied development programs.

Asia Pacific

Asia Pacific represented 23.6% of CircRNA Synthesis Market revenue in 2025. Asia Pacific growth is supported by expanding biotechnology ecosystems, increasing R&D intensity, and rising demand for accessible synthesis toolkits and scalable service options. Asia Pacific also benefits from growing cross-border collaborations and increased investment in RNA platform technologies.

Latin America

Latin America accounted for 1.1% of CircRNA Synthesis Market revenue in 2025. Latin America adoption remains early-stage, with demand concentrated in selected research hubs where RNA and advanced therapeutics activity is expanding. Latin America opportunity is linked to improving research infrastructure and broader access to outsourced synthesis services.

Middle East & Africa

Middle East and Africa accounted for 0.6% of CircRNA Synthesis Market revenue in 2025. Middle East and Africa activity remains nascent, with adoption primarily linked to specialized research centers and emerging innovation programs. Middle East and Africa growth potential depends on expanding translational research capacity and procurement accessibility.

Competitive Landscape

CircRNA Synthesis Market competition includes a mix of catalog reagent suppliers, custom synthesis specialists, and multi-omics service platforms that compete on turnaround time, synthesis reliability, and documentation quality. CircRNA Synthesis Market differentiation is increasingly shaped by end-to-end workflow coverage, where vendors bundle design support, circularization optimization, purification, and verification. CircRNA Synthesis Market participants also compete through breadth of catalog offerings and the ability to support both discovery-scale and more controlled development-stage requirements. CircRNA Synthesis Market buyers commonly evaluate vendors on reproducibility, technical support depth, and capability to customize workflows for different constructs.

GenScript is positioned as a prominent provider across research tools and custom services that can support RNA-adjacent workflows through synthesis capabilities, workflow guidance, and standardized delivery processes. GenScript can benefit from cross-selling opportunities where customers procure reagents and services together to reduce workflow fragmentation. GenScript differentiation typically centers on service execution capability and the ability to support multiple stages of R&D from exploratory work through more structured development needs. GenScript also competes by offering technical support and process standardization that reduces adoption friction for complex synthesis workflows.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• GenScript
• Azenta / GENEWIZ
• Creative Biogene
• Creative Biolabs
• LGC Biosearch Technologies
• SBS Genetech
• Applied Biological Materials (abm)
• Amerigo Scientific
• BOC Sciences
• GeneCopoeia
• Guangzhou Geneseed Biotech
• VectorBuilder
• Thermo Fisher Scientific

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Developments

• In December 2025, uBriGene Biosciences and Circurna announced a strategic partnership to accelerate the development and manufacturing of circular RNA/LNP therapeutics. In this collaboration, uBriGene agreed to support process and analytical development, scale-up, and GMP production, while Circurna contributes its proprietary circRNA platform to move programs toward the clinic.
• In June 2025, Circio Holding ASA and NeoRegen Biotech expanded their ongoing partnership by signing a second Material Transfer Agreement to move their circular RNA delivery collaboration into the in vivo preclinical stage. The update centers on combining Circio’s circVec expression platform with NeoRegen’s NICT delivery technology to validate targeted and durable intracellular delivery for future therapeutic development.
• In May 2025, Altamira Therapeutics announced a collaboration agreement with an undisclosed partner to evaluate its CycloPhore platform for delivering circular RNA payloads. The company said the project will test the platform in vitro and in vivo, and the partner may later negotiate a licensing agreement to develop and commercialize circRNA nanoparticles.

Report Scope

Segmentation

By Product & Service

• Reagents & Kits
• Instruments
• Services

By Application

• Therapeutics Development
• Drug Discovery
• Other Applications

By End Use

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa